Active — Not RecruitingNot Applicable

Efficacy and Safety of Zotarolimus-eluting Stent Overexpansion With OCT

South Korea30 participantsStarted 2022-03-23

Plain-language summary

Investigators aimed to evaluate efficacy and safety of expansion capacity of zotarolimus-eluting Stent assessed by optical coherence tomography (OCT) in vivo study.

Who can participate

Age range19 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients, ≥19 years of age, who were diagnosed with IHD requiring stent implantation for lesion with size discrepancy between proximal and distal reference diameter over 1mm, such as tapered long lesion or bifurcation lesion, confirmed by OCT * The decision to participate voluntarily in this study and the written consent of the patient Exclusion Criteria: * Patients with hypersensitivity or contraindication to antiplatelet treatment * Female of childbearing potential, who possibly plans to become pregnant any time after enrollment into this study. * Patients with a life expectancy shorter than 1 year

What they're measuring

Maximal stent overexpansion (%)

Timeframe: Through procedure completion, up to 24 hours

Trial details

NCT IDNCT05340361

SponsorYonsei University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-12-31

View on ClinicalTrials.gov More Coronary Artery Disease trials